The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Eisai
Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial.
 
Jun J. Mao
Research Funding - Tibet Cheezheng Tibetan Medicine Co., Ltd. (Inst); Zhongke Health (Inst)
 
Kevin Liou
No Relationships to Disclose
 
Katherine Panageas
Stock and Other Ownership Interests - AstraZeneca; Catalyst Biotech; Dynavax Technologies; Pfizer; Sunesis Pharmaceuticals; Viking Therapeutics
 
Raymond E Baser
No Relationships to Disclose
 
Sally A. D. Romero
No Relationships to Disclose
 
Qing Susan Li
No Relationships to Disclose
 
Han Xiao
No Relationships to Disclose
 
Ting Bao
No Relationships to Disclose
 
Philip W. Kantoff
Leadership - Context Therapeutics
Stock and Other Ownership Interests - Context Therapeutics; Druggablity Technologies; Placon; Seer
Consulting or Advisory Role - Bavarian Nordic; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; Seer; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties